In summary, DUXAP8 competitively bound to miR-584-5P through the ceRNA mechanism (Figure 8), thus targeting MAPK1 and activating the MAPK/ERK pathway to regulate the malignant phenotype and chemotherapy resistance of HCC. Here, DUXAP8 is linked to hepatocellular carcinoma.